BRAF and melanoma: Importantly, under hypoxic conditions, AZD7762 kills cells both sensitive and resistant to BRAF inhibition and induces a significant tumor growth delay in vivo in PDX melanoma cells with primary resistance to vemurafenib (PLX4032) [70].